John Poneros, MD
Gastroenterology · New York, NYNPI 1164413332
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $12,000 of the $17,055 with a category attached, or 70.4%. Boston Scientific accounts for 90.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $13,885 and has fallen 94.1% since, to $821 in 2025.
Across 95 payments — averaging $179.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- AbbVie$372
- Olympus America Inc.$273
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$270
- Takeda Pharmaceuticals U.S.A., Inc.$180
- Steris Corporation$144
- plus $453 from 10 others
What the payments were for
- Speaking & faculty fees$12,00070%
- Grants$5003%
- Travel & lodging$1,1977%
- Food & beverage$3,35720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 33 | $15,362 |
| AbbVie(2 entities) | 19 | $372 |
| Olympus America Inc. | 4 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $270 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $180 |
| Steris Corporation | 1 | $144 |
| Medtronic | 1 | $126 |
| Amgen | 3 | $89 |
| UCB, Inc. | 2 | $53 |
| Merck | 3 | $44 |
| Cook Medical LLC | 1 | $28 |
| Shire North American Group Inc | 1 | $25 |
| Redhill Biopharma Inc. | 1 | $25 |
| Pentax Of America, Inc. | 1 | $23 |
| Ardelyx, Inc. | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL - BILIARY DEVICES$919
- AXIOS$164
- APOLLO ESG System$153
- TRUFREEZE$144
- EXALT Model D$136
- GI Genius$126
How this compares
$17,055 in reported general payments places this provider in the 85th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 23 | $2,333 |
| Pantoprazole Sodium | 11 | $196 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in New York
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
- Sonal KumarNew York$1M
- David PoppersNew York$939K
- Ellen ScherlNew York$857K
- Bruce SandsNew York$810K
- Jean Frederick ColombelNew York$786K
- Seth GrossNew York$624K
- Caterina Oneto ArayaNew York$610K
- Dana LukinNew York$491K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.